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Abstract
Transcriptome-wide association studies based on genetically predicted gene expression have
the potential to identify novel regions associated with various complex traits. It has been shown
that incorporating expression quantitative trait loci (eQTLs) corresponding to multiple tissue
types can improve power for association studies involving complex etiology. In this article, we
propose a new multivariate response linear regression model and method for predicting gene
expression in multiple tissues simultaneously. Unlike existing methods for multi-tissue joint
eQTL mapping, our approach incorporates tissue-tissue expression correlation, which allows
us to more efficiently handle missing expression measurements and more accurately predict
gene expression using a weighted summation of eQTL genotypes. We show through simulation
studies that our approach performs better than the existing methods in many scenarios. We
use our method to estimate eQTL weights for 29 tissues collected by GTEx, and show that
our approach significantly improves expression prediction accuracy compared to competitors.
Using our eQTL weights, we perform a multi-tissue-based S-MultiXcan [2] transcriptome-wide
association study and show that our method leads to more discoveries in novel regions and
more discoveries overall than the existing methods. Estimated eQTL weights are available for
download online at github.com/ajmolstad/MTeQTLResults
1 Introduction
Genome-wide association studies (GWAS) have identified tens of thousands of reproducible trait
associated single-nucleotide polymorphisms (SNPs) through agnostic SNP-by-SNP association anal-
ysis (see https://ebi.ac.uk/gwas/) [4]. Though most of these associated SNPs lie outside of any
gene, they are enriched for expression quantitative trait loci (eQTL)[14, 23, 27], which are genetic
loci that affect the expression of one or more genes [6, 25, 31, 34, 36]. Machine learning methods
have been used to infer eQTL regulation of a gene using all nearby genetic variants [9, 22, 46]. Using
genetically predicted gene expression from these models, researchers have performed transcriptome-
wide association studies (TWAS) and reported many novel regions associated with various complex
traits [13, 29, 21, 1], many of which have no GWAS association within 1Mb. There are several
advantages to such analyses: leveraging gene expression enriches potential trait associated SNPs,
aggregating signals through joint eQTL modeling enhances the overall association strength, and
the number of tests is substantially reduced from testing millions of SNPs to about 20,000 genes.
∗amolstad@ufl.edu
1
ar
X
iv
:2
00
1.
08
36
3v
1 
 [s
tat
.A
P]
  2
3 J
an
 20
20
Figure 1: A heatmap of missingness in GTEx gene expression data for the 29 tissues we analyzed.
Rows correspond to the 29 tissues and columns correspond to the 613 subjects with expression
measured in at least one of the corresponding tissues. White spaces denote missing measured
expression, whereas black denote observed measured expression.
Because of the tissue-dependent nature of gene expression, these analyses typically use gene expres-
sion from a single trait-relevant tissue. However, recent works have shown that eQTLs are often
shared across multiple tissues and assessing the association of genetically predicted gene expression
using multiple tissues improves power for genetic association with complex traits [1, 2].
Leveraging shared eQTLs across tissues improves power for eQTL discoveries and gene ex-
pression imputation accuracy, which can, in turn, further improve power for transcriptome-wide
association analysis. Flutre et al. [8] and Li et al. [20] proposed multi-tissue eQTL mapping ap-
proaches that identified more eQTLs than tissue-by-tissue approaches. More recently, Hu et al. [16]
proposed a penalized regression approach for joint modeling of eQTLs using a penalty which encour-
ages shared eQTLs across tissues. Using the genotype and expression data for various tissues from
the Genotype-Tissue Expression (GTEx) project [11, 12], they showed multi-tissue eQTL models
improve imputation accuracy and gene association detection substantially compared to single-tissue
approaches.
However, the method of Hu et al. [16] does not take into account tissue-tissue correlation of gene
expression in joint eQTL modeling. In the recent statistical literature, it has been shown that in
high-dimensional penalized multivariate response linear regression, accounting for error correlation
(here, tissue-tissue correlation) often leads to improved variable selection and prediction accuracy
[33, 43, 39, 19]. This phenomenon can be partly explained by a seemingly unrelated regression
interpretation of high-dimensional sparse multivariate response linear regression [45, 35]. Further,
owing to biological and cost constraints, some tissue types are harder to obtain than others. For
example, of the 29 GTEx tissues we focus on in our analysis, there were 613 individuals with
expression measured in at least one tissue of interest. Some individuals have as few as one tissue
with measured expression, whereas others have expression measured in as many as 28 tissues. No
individual has expression measured in all 29 tissues. The sample size per tissue varies from 85
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(Minor Salivary Gland) to 491 (Muscle - Skeletal) (Figure 1). We show that leveraging tissue-
tissue correlation can substantially improve gene expression prediction accuracy, especially for
tissues with small sample sizes. We do so by imputing the missing gene expression in a way which
simultaneously estimates tissue-tissue correlation and joint eQTL weights: the mechanism through
which this operates is straightforward, for example, if two tissues’ expression is highly correlated,
measuring expression in only one of these tissues allows one to reasonably estimate expression in
the unmeasured tissue. If tissue-tissue correlation is ignored, substantial gains in gene expression
prediction accuracy may be lost.
In this article, we propose a new method for multi-tissue joint eQTL mapping which can be used
when individuals have missing gene expression measurements in many tissues. We develop an ef-
ficient penalized expectation-conditional-maximization (ECM) algorithm to solve the optimization
problem. Our penalties allow us to identify both tissue specific and shared eQTLs while simultane-
ously modeling cross-tissue expression covariance. Compared to existing methods for multi-tissue
joint eQTL mapping, our approach has several advantages:
• our method explicitly models tissue-tissue correlation, providing new insights about cross-
tissue expression dependence which cannot be explained by eQTLs;
• by modeling cross-tissue correlation, our method more efficiently makes use of the available
expression measurements for eQTL weight estimation;
• our computational approach can be used to more efficiently compute special cases of our
method, e.g., the method of Hu et al. [16];
• in both simulations and our analysis of the GTEx data, our approach leads to improved
gene expression prediction accuracy compared to (a) tissue-by-tissue approaches which esti-
mate eQTL weights separately; (b) two-step approaches where imputation and prediction are
performed in sequential steps; and (c) approaches which ignore cross-tissue correlation.
The implication of the final point on association analyses of genetically predicted gene expression is
immediate: with more accurate expression prediction models, one can perform more reliable tests,
and thus, can expect more novel regions to be discovered. In particular, with the weights estimated
from the GTEx data using our method, we performed a multi-tissue-based S-MultiXcan[2] TWAS
analysis of four complex traits. We found that our weights led to more total discoveries and more
novel discoveries beyond single variant analyses than existing methods in four traits we studied.
Focusing on genes associated with the occurrence of a heart attack, we identified multiple regions
which were not attributable to any GWAS associated SNP, but have been associated with traits
related to heart function, e.g., coronary heart disease, triglyceride levels, and LDL cholesterol.
These findings demonstrate the potential power gain using an integrative analysis with multiple
tissues and also offer insight into potential factors associated with the occurrence of a heart attack.
Discovered genes from our S-MultiXcan analysis, along with our estimated eQTL weights, are
available for download at github.com/ajmolstad/MTeQTLResults.
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2 Method
2.1 Penalized maximum likelihood estimator
Throughout, we will assume a general model for cross-tissue expression given SNP genotypes. For
a particular gene, let yi ∈ Rq denote the vector of centered and normalized measured expression
in q tissues for the ith subject and let xi ∈ Rp denote the p SNP genotypes (also centered and
normalized) within a certain distance (e.g., 500kb) of the transcription start and end site of the
gene of interest. We assume that for the ith subject, measured expression is a realization of the
random vector
Yi = β′∗xi + i, i ∼ Nq
(
0,Ω−1∗
)
, (i = 1, . . . , n) (1)
where Nq denote the q-dimensional multivariate normal distribution, β∗ ∈ Rp×q is the unknown
regression coefficient matrix (i.e., eQTL weights), and Ω∗ ∈ Sq+ is the cross-tissue error precision (in-
verse covariance) matrix. We further assume that i is independent of j for all i 6= j. Throughout,
we let Sq+ denote the set of q × q symmetric and positive definite matrices.
We estimate β∗ and Ω∗ jointly by minimizing the observed-data penalized negative log-likelihood
with respect to β and Ω, the optimization variables corresponding to β∗ and Ω∗, respectively. Let
oi and mi denote the components of yi (tissues) which are observed and missing, respectively, so
that without loss of generality, we can write yi = (y
′
i,oi
, y′i,mi)
′ ∈ Rq where A′ denotes the transpose
of matrix or vector A and yi,oi denotes the subvector of yi corresponding to the indices oi. Thus,
the observed-data negative log-likelihood (ignoring constants) for the n subjects is proportional to
1
n
n∑
i=1
[
tr
{
(yi,oi − x′iβ·,oi)′Σ−1oi (yi,oi − x′iβ·,oi)
}
+ log det (Σoi)
]
, (2)
where Σoi ∈ S#oi+ is the submatrix of Σ corresponding to the indices oi, β·,oi ∈ Rp×#oi is the
submatrix of β containing columns corresponding to the indices oi, and #oi denotes the cardinality
of oi. Throughout, tr and det denote the trace and determinant operators, respectively. Note that
for notational simplicity, we assume that yi and xi have column-wise average zero, so that we can
write (1) without an intercept.
Unfortunately, minimizing (2) directly is computationally difficult since missingness patterns
differ across subjects. Instead, we use an expectation-maximization (EM) algorithm, which allows
us to operate on the complete-data negative log-likelihood. Let YO denote the collection of the yi,oi ’s
for i = 1, . . . , n, i.e., YO is the collection of all observed gene expression for the n subjects. Similarly,
let YM denote the collection of all unmeasured (missing) gene expression for the n subjects. Thus,
we rewrite the observed-data negative log-likelihood F(β,Ω;YO) in terms of the complete-data
negative log-likelihood:
F(β,Ω;YO) = − 1
n
n∑
i=1
log
∫
fY(β,Ω; yi,oi , yi,mi)∂Yi,mi , (3)
where fY denotes the q-dimensional multivariate normal density.
To estimate β∗ and Ω∗ simultaneously while accounting for missingness, we propose to minimize
a penalized version of F(β,Ω;YO) with respect to β and Ω jointly. Specifically, we estimate (β∗,Ω∗)
with
arg min
β∈Rp×q ,Ω∈Sq+
{
F(β,Ω;YO) + λβP(α)β (β) + λΩPΩ(Ω)
}
, (4)
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where λβ and λΩ are non-negative tuning parameters; and P(α)β and PΩ are convex penalty functions
applied to β and Ω, respectively. The penalties are chosen based on the biology underlying multi-
tissue joint eQTL mapping. In particular, it is believed that large proportion of eQTLs are shared
across multiple tissues in most genes [8, 20, 16], which would imply that nonzero entries of β∗ are
likely to occur in a subset of rows since each row of β∗ corresponds to a particular SNP’s regression
coefficients (eQTL weights) for the q tissues. To exploit this assumption, we use a penalty which
balances row-wise sparsity with element-wise sparsity:
P(α)β (β) =
p∑
j=1
{
α
(
q∑
k=1
|βj,k|
)
+ (1− α)‖βj,·‖2
}
, (5)
where α ∈ [0, 1] is a tuning parameter, ‖·‖2 denotes the Euclidean norm of a vector, and βj,· ∈ Rq is
the jth row of β (j = 1, . . . , p). If α were set to zero, estimates of β∗ would only have rows which are
entirely zero or nonzero. Conversely, when α = 1, this penalty does not encourage eQTL sharing
explicitly. The penalty in (5) was also used by Peng et al. [30] in the context of the multivariate
response linear regression model of gene expression on copy number alterations.
To estimate the cross-tissue error precision matrix Ω∗, we use an `1-penalty on the entries of
the corresponding optimization variable: PΩ(Ω) =
∑
j,k |ωj,k|. For sufficiently large values of the
tuning parameter λΩ, this penalty leads to estimates of the precision matrix which will have all
off-diagonal entries equal to zero [44, 32]. Hence, this penalty implicitly assumes that some entries
of Ω∗ equal zero. This assumption is also biologically reasonable in the context of multi-tissue joint
eQTL mapping: it is well known that under (1), a zero in the (j, k)th entry of Ω∗ implies that
expression in the jth and kth tissues are independent given expression in all other tissues and all
p SNP genotypes.
2.2 Penalized expectation-conditional-maximization algorithm
To obtain the penalized maximum likelihood estimator, i.e., to solve (4) with the penalties in (5)
and PΩ(Ω), we propose a penalized expectation-conditional-maximization (ECM) algorithm [24].
Let Gλ denote the penalized complete-data negative log-likelihood so that
Gλ(YO, YM ;β,Ω) = − 1
n
n∑
i=1
log fY(β,Ω; yi,oi , yi,mi) + λβP(α)β (β) + λΩPΩ(Ω)
where λ = (α, λβ, λΩ) ∈ [0, 1] × R+ × R+ is fixed. The standard EM algorithm proceeds in two
steps: the E-step
Q(β,Ω | β(k),Ω(k)) = E
[
Gλ(YO, YM ;β,Ω) | YO, β(k),Ω(k)
]
,
and the subsequent M-step
(β(k+1),Ω(k+1)) ∈ arg min
β∈Rp×q ,Ω∈Sq+
Q(β,Ω | β(k),Ω(k)). (6)
However, solving (6) exactly requires a blockwise coordinate descent algorithm iterating between
updating Ω and β. Instead, we propose to update each variable once (with the other held fixed) and
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then return to the E-step. In this way, our approach can be considered a generalized expectation-
conditional-maximization algorithm in the sense that we do not solve the M-step exactly at each
iteration, but are guaranteed that the objective function is non-increasing. An outline of the com-
plete algorithm is given in Algorithm 1.
Algorithm 1: (Penalized ECM) Initialize optimization variables. Set k = 1.
1. Compute Q(β,Ω | β(k),Ω(k)) = E [Gλ(YO, YM ;β,Ω) | YO, β(k),Ω(k)]
2. Compute Ω(k+1) ← arg minΩ∈Sq+ Q(β(k),Ω | β(k),Ω(k)).
3. Compute β(k+1) ← arg minβ∈Rp×q Q(β,Ω(k+1) | β(k),Ω(k)).
4. If the objective value from (4) has not converged, set k = k + 1 and return to Step 1.
Because the updates for Ω and β (with the other held fixed) are both convex optimization
problems, the M-step is an instance of a biconvex optimization problem. In the following subsection,
we describe how to solve Steps 1-3 of the penalized ECM algorithm.
2.3 Algorithm details
To compute the Q function in Step 1 (E-Step) of Algorithm 1, we use the conditional multivariate
normal distribution for yi,mi given yi,oi and the current iterates of β and Ω:
(yi,mi | yi,oi , β(k),Ω(k)) ∼ N#mi
(
µ
(k)
i,mi
, V
(k)
i,mi
)
, i = 1, . . . , n, (7)
where the mean and variance from (7) can be expressed in closed form:
µ
(k)
i,mi
= β
(k)
·,mi
′
xi + Σ
(k)
mi,oiΣ
(k)−1
oi (yi,oi − β
(k)
·,oi
′
xi);
V
(k)
i,mi
= Σ(k)mi − Σ(k)mi,oiΣ(k)−1oi Σ(k)oi,mi
with Σ
(k)
mi,oi denoting the submatrix of Σ
(k) whose rows correspond to the indices of mi and whose
columns correspond to indices of oi, i.e., Σ
(k)
oi ≡ Σ(k)oi,oi and Σ(k)mi ≡ Σ(k)mi,mi .
With µ
(k)
i,mi
and V
(k)
i,mi
computed and stored for i = 1, . . . , n, we can then express Step 2 of
Algorithm 1 as a familiar convex optimization problem.
Remark 1. Let β(k) and Σ(k) be fixed. Then, Step 2 of Algorithm 1 can be expressed as
Ω(k+1) = arg min
Ω∈Sp+
tr{S(β(k),Σ(k))Ω}− log det(Ω) + λΩ∑
j,k
|ωj,k|
 (8)
where S(β(k),Σ(k)) = n−1
∑n
i=1 Γ
(k)
i for i = 1, . . . , n with the submatrices of each Γ
(k)
i equal to
[Γ
(k)
i ]oi = (y
′
i,oi − x′iβ
(k)
·,oi)
′(y′i,oi − x′iβ
(k)
·,oi);
[Γ
(k)
i ]mi = (µ
(k)′
i,mi
− x′iβ(k)·,mi)′(µ(k)
′
i,mi
− x′iβ(k)·,mi) + V (k)i,mi ;
[Γ
(k)
i ]oi,mi = (y
′
i,oi − x′iβ
(k)
·,oi)
′(µ(k)i,mi − x′iβ
(k)
·,mi).
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Conveniently, (8) is exactly the optimization problem for computing the `1-penalized normal
log-likelihood precision matrix estimator with input sample covariance matrix S(β(k),Σ(k)). Many
efficient algorithms and software packages exist for computing (8): in our implementation, we use
glasso in R [42].
Step 3 of Algorithm 1, the update for β with Ω(k+1) fixed, can be expressed as a minimizer of
a penalized weighted residual sum of squares criterion, which we formalize in Remark 2.
Remark 2. Let β(k), Ω(k), and Ω(k+1) be fixed. Then, Step 3 of Algorithm 1 can be expressed as
β(k+1) = arg min
β∈Rp×q
[
1
n
tr
{
(Y¯ (k) −Xβ)Ω(k+1)(Y¯ (k) −Xβ)′
}
+ λβP(α)β (β)
]
(9)
where Y¯ (k) ∈ Rn×q has ith row Y¯ (k)i,(oi,mi) = (y′i,oi , µ
(k)′
i,mi
)′ for i = 1, . . . , n.
Note that the notation Yi,(a) denotes the permutation of the elements of the vector Yi corre-
sponding to an index set a. For example, were a = (2, 1) and Ui ∈ R2, Ui,(a) = (Ui,2, Ui,1)′.
To solve (9), we use an accelerated proximal gradient descent algorithm [28]. We briefly motivate
this iterative procedure from a majorize-minimize perspective [18]. Let h : Rp×q → R denote the
unpenalized objective function from (9), i.e., the objective function from (9) with λβ = 0. Let
‖A‖2F = tr(A′A) =
∑
j,k A
2
j,k denote the squared Frobenius norm of a matrix A. Then, given some
iterate of β which is fixed, say β(r), because h is convex and has Lipschitz continuous gradient,
h(β) ≤ h(β(r)) + tr
{
∇h(β(r))′(β − β(r))
}
+
1
2γ
‖β − β(r)‖2F
for all β with γ > 0 sufficiently small. Hence, it follows that
h(β) + λβP(α)β (β) ≤ h(β(r)) + tr
{
(β − β(r))′∇h(β(r))
}
+
1
2γ
‖β(r) − β‖2F + λβP(α)β (β) (10)
for all β where ∇h(β(r)) is the gradient of h evaluated at β(r). Thus, if we minimize the right hand
side of (10) with respect to β, which after some algebra can be expressed as
β(r+1) = arg min
β∈Rp×q
{
1
2
‖β − β(r) + γ∇h(β(r))‖2F + γλβP(α)β (β)
}
, (11)
we are guaranteed that the objective function from (9) evaluated at β(r+1) is less than or equal to
the objective function evaluated at β(r). This suggests a simple iterative procedure to solve (9): in
the first step, we construct the “majorizing function”[18] from the right hand side of (10) at the
current iterate; in the second step, we minimize this majorizing function to obtain our new iterate;
and then we repeat these two steps until the objective function from (9) converges.
This approach is computationally efficient because (11) can be solved in closed form with the
following steps:
(a) Compute ∆ = β(r) − γ∇h(β(r));
(b) Compute ∆¯j,k = max (|∆j,k| − γλβα, 0) sign(∆j,k) for all (j, k) ∈ [1, . . . , p]× [1, . . . , q]
(c) Compute β
(r+1)
j,· = max
(
1− γλβ(1−α)‖∆¯j,·‖2 , 0
)
∆¯j,· for j = 1, . . . , p
For the complete algorithm to solve (9), steps (a) - (c) are repeated until the objective function
converges. In the Supplementary Material, we give the exact steps of the accelerated version this
algorithm which we use in our implementation and discuss selecting the step size γ.
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2.4 Related methods
A special case of our method was proposed by Hu et al. [16]. In particular, the objective function
they propose to estimate eQTL weights is equivalent to (4) with the constraint that Ω = Iq, i.e.,
they implicitly assume that gene expression is uncorrelated with equal variance after conditioning
on SNP genotypes. However, Hu et al. [16] do not solve the optimization problem they posed
directly. Instead, they devised an efficient coordinate descent scheme which approximated their
estimator. While their approximation performed well in terms of predicting expression, comparing
our method to theirs directly is difficult: it is not clear when to terminate their iterative procedure
because their algorithm does not minimize an objective function whose value can be computed.
Hence, we compare our approach, which assumes only Ω ∈ Sq+, to what we refer to as the exact
version of the Hu et al. [16] (i.e., (4) with the constraint Ω = Iq) in our simulation studies, the
GTEx data analysis, and the S-MultiXcan TWAS. To compute the estimator of Hu et al. [16], we
use a proximal gradient descent algorithm similar to that used for the optimization problem in (9).
Details about this algorithm are provided in the Supplementary Material.
3 Simulation studies
3.1 Data generating models and competing methods
We performed extensive numerical experiments to study how the number of shared eQTLs, the
population R2, and tissue-tissue correlation structure affect the performance of various methods
for estimating multi-tissue eQTL weights.
To closely mimic the settings of the joint eQTL mapping in the GTEx data, we obtained whole
genome sequencing SNP genotype data for all SNPs within 500kb of the BRCA1 gene for 620
subjects from the GTEx dataset. After pruning SNPs with extremely high correlations (see Data
Preparation section), we are left with p = 1178 SNP genotypes. For each replication, we then
generated n = 620 subjects’ expression in q = 29 tissues: letting xi ∈ Rp be the SNP genotypes for
the ith subject, we generated yi ∈ Rq, as a realization of the random vector
β′∗xi + i, i = 1, . . . , n,
where β∗ ∈ Rp×q are the eQTL weights and i ∼ Nq(0,Ω−1∗ ) are independent and identically
distributed errors. For one hundred independent replications in each setting, we randomly split the
n = 620 subjects into a training set of size ntrain = 400, a validation set of size 110, and a testing
set of size 110.
Independently in each replication, we generated β∗ as follows: first, we generated B ∈ Rp×q to
have entries which were independent N(0, 1). Then, we generated S ∈ Rp×q to be a matrix whose
rows are either all zero or all one: we randomly select s rows to be nonzero, where s ∈ {1, . . . , 20}.
Given S, we then generated U ∈ Rp×q so that each of the q columns has 20-s randomly selected
entries equal to one only from entries which are zero in S and all others equal to zero. With these,
we set β∗ = B ◦ S + B ◦ U where ◦ is the elementwise product. By constructing β∗ in this way,
each tissue has twenty total eQTLs, s of which are shared across all tissue types. We consider
s = {5, 10, 15, 18, 20} in the simulations we present in this section. Note that since many SNPs
are highly correlated (linkage disequilibrium), marginally, there are far more SNPs associated with
gene expression.
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We constructed Ω−1∗ to have a block-diagonal structure and to control the R2. Specifically, we
set Ω−1∗ = DEΣEDE where DE ∈ Rq×q is a diagonal matrix with positive entries and ΣE ∈ Sq+ is a
positive definite correlation matrix. In our analysis of the GTEx data, we found that on average,
the estimated correlation matrix had an approximately 20×20 correlated block, of which a 10×10
sub-block was more highly correlated. Thus, we set
[ΣE ]j,k =

ρ for (j, k) where 11 ≤ j ≤ 20, 11 ≤ k ≤ 20, and j 6= k
ρ+ 0.2 for (j, k) where 1 ≤ j ≤ 10, 1 ≤ k ≤ 10, and j 6= k
1 for (j, k) where j = k
0 otherwise
In the results presented here, we considered ρ ∈ {0, 0.1, 0.3, 0.5, 0.7}. Given ΣE and β∗, we
then generated entries of DE to determine the R
2 for all q = 29 tissues: we considered R2 ∈
{.01, .05, .10, .20, .40}.
Finally, we also randomly assigned missingness to both the training set and validation set re-
sponses with missing probability equal to 0.55, i.e., the missing rate in the GTEx gene expression
data we analyzed. For each method, we fit the model to the training data, selected tuning parame-
ters using the validation data, and measured the prediction and variable selection accuracy on the
testing data.
We considered three different methods: two of which can be considered “complete-case” esti-
mators. We define the missingness matrix M ∈ Rntrain×q as:
Mi,k =
{
n
−1/2
k : yi,k was observed
0 : yi,k was missing
(i, k) ∈ {1, . . . , ntrain} × {1, . . . , q} ,
where nk is the number of subjects with expression observed for the kth tissue in the training
data. Similarly, let Y ∈ Rntrain×q be the fully-observed gene expression training data matrix, and
X ∈ Rntrain×p the SNP genotypes for the training data. The methods we compared are:
• EN: The tissue-by-tissue elastic net defined as
arg min
β∈Rp×q
 12n‖(Y −Xβ) ◦M‖2F +
q∑
k=1
λk
αk p∑
j=1
|βj,k|+ (1− αk)
p∑
j=1
β2j,k
 ,
where for k = 1, . . . , q, each (λk, αk) ∈ R+ × [0, 1] is chosen to maximize the validation set
R2 for the kth response variable. This is the default method for estimating eQTL weights in
Gamazon et al. [9].
• MT: The exact version of the method proposed by Hu et al. [16]:
arg min
β∈Rp×q
{
1
2n
‖(Y −Xβ) ◦M‖2F + λβP(α)β (β)
}
, (12)
where λβ > 0 and α ∈ [0, 1] are chosen to maximize validation set R2 averaged over all 29
tissues. As explained in the previous section, this is a special case of our method with the
restriction that Ω = Iq.
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• Cov-MT: The model-based approach we proposed in (4):
arg min
β∈Rp×q ,Ω∈Sq+
{
F(β,Ω;YO) + λβP(α)β (β) + λΩPΩ(Ω)
}
,
where tuning parameters λβ > 0, λΩ > 0, and α ∈ [0, 1] are chosen to maximize the validation
set R2 averaged over all 29 tissues.
We also obtained oracle estimators Or-EN and Or-MT, which are equivalent to EN and MT without
any missingness. Here Or stands for “Oracle”, i.e., an estimator which has information not available
in practice. These estimators replace M with an Rntrain×q matrix with each entry equal to n−1/2train .
These estimators are meant to compare to the idealized setting where there is no missingness in the
response to distinguish between the effects of missingness and the effects of ignoring tissue-tissue
correlation.
Finally, we also considered KNN(20)-MT, which first imputes the missing responses using a
weighted mean based on the 20-nearest neighbors (subjects) and then used the same criterion as
Or-MT to estimate β∗. We also tried imputation via k-nearest neighbors with k ∈ {2, 5, 10, 50}, but
results did not differ substantially across these choices of k, so additional results are omitted.
We measured performance using three metrics. The metric we used to measure prediction
accuracy was average test-set R2. Specifically, for a given estimate of β∗, we obtain the predicted
value of Ytest ∈ Rntest×q, say Yˆ ∈ Rntest×q, and compute
Rˆ2 =
1
q
{
q∑
k=1
(
1− ‖Ytest,k − Yˆ·,k‖
2
2
‖Ytest,k − Y¯train,k‖22
)}
,
where Y¯train,k = 1ntest
[
n−1k
∑ntrain
i=1 yik1(yik was observed)
]′
where 1ntest ∈ Rntest is a vector of ones
and 1(·) denotes the function which equals one if its argument is true and zero if false. Note that
this definition allows for the possibility that the test-set R2 is less than zero which would occur
when the training sample mean predicts Ytest better than the estimate of β∗. We also measured
the linkage disequilibrium (LD)-adjusted true positive rate, which we define as∑q
k=1
[∑p
j=1 1
(
[βˆ∗]j,k 6= 0 ∩ [βˆ]l,k 6= 0 for any l ∈ {l : |Cor(X·,l, X·,j)| > 0.60}
)]
∑q
k=1
∑p
j=1 1([β∗]j,k 6= 0)
. (13)
The LD-adjustment accounts for the fact that SNP genotypes are often highly correlated. Under
our data generating model, we consider an eQTL discovery “true” if the selected SNP genotype is
moderately correlated with a true eQTL (i.e., predictor whose corresponding regression coefficient
is nonzero).
In addition to true positive rate, we also measured model size, i.e., the proportion of nonzero
entries of the estimated regression coefficient matrix. Note that under our data generating models,
the true model size is approximately .017, i.e., (20/p), but because SNPs are so highly correlated,
much larger estimated models could be expected.
3.2 Simulation study results
We present complete simulation study results in Figure 2. In the top row, (a), we present results
with tissue-tissue correlation ρ ∈ {0.0, 0.1, 0.3, 0.5, 0.7} varying, the population R2 fixed at 0.10,
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Figure 2: Average test set R2, average LD-adjusted true positive rate, and average model size
(proportion) for six competing methods where: (a) ρ, the correlation of the errors varies; (b) the
population R2 varies; and (c) the proportion of the twenty eQTLs which are shared across all 29
tissues varies. Error bars denote two times the standard error for each method. Note that the
spacing on the horizontal axes is not proportional to the difference in values represented on the
horizontal axes. In the leftmost plot of the (b), error bars are not visible due to the range of the
vertical axis. Note that throughout, the default settings were R2 = 0.1, the proportional of shared
eQTLs was equal to 0.15, and ρ = 0.50.
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and the proportion of shared eQTLs fixed at 0.75 (i.e., s = 15). In this setting, we observe that our
method, Cov-MT performs better than all realistic competitors: only Or-MT, the version of MT which
does not have any responses missing, outperforms our method when ρ is less than 0.5. As one would
expect, when expression is nearly uncorrelated (ρ = 0), our method Cov-MT performs similarly to the
exact version of the method of Hu et al. [16], which implicitly assumes no tissue-tissue correlation.
Remarkably, when ρ is greater than or equal to 0.50, Cov-MT outperforms even the “Oracle” methods
which have no missingness. In fact, the prediction accuracy of Cov-MT increases as ρ increases,
whereas all other methods, which do not explicitly model tissue-tissue correlation, have prediction
accuracy remaining constant or slightly decreasing as ρ increases. This demonstrates the benefit of
accounting for tissue-tissue correlation in multi-tissue joint eQTL mapping when expression across
tissue types can be reasonably assumed to be conditionally dependent. It is also notable that EN
performs very poorly: this is partly attributable to the fact that this approach does not leverage
potential eQTLs shared across tissues, and thus, has relatively poor variable selection of eQTLs,
which is apparent from the results displayed in the middle figure of row (a).
As ρ increases, the LD-adjusted true positive rate (TPR) of our method tends towards one,
whereas for many of the competitors, the true positive rate decreases as ρ increases. This may
partly be due to the fact that these methods tend to estimate fewer eQTLs as ρ increases, which
is demonstrated in the rightmost figure of row (a). Notably, all methods tend to yield much larger
models than the true model. Finally, we also observe that our method significantly outperforms the
20-nearest neighbor two-step imputation approach (KNN(20)-MT), which first imputes missing values
via k-nearest neighbor and then fits the Or-MT model to the imputed dataset. This demonstrates
the importance of jointly estimating the model parameters and performing expression imputation.
In the middle row, (b), of Figure 2, we present results with R2 ∈ {0.01, 0.05, 0.1, 0.2, 0.4}, the
proportion of shared eQTLs fixed at 0.75, and ρ = 0.50 fixed. We observe that our method performs
as well or better than competitors across all settings in terms of average test set R2, except for
when R2 = 0.40, in which case Or-MT performs best. Interestingly, our method also performs best
in terms of LD-adjusted TPR for small R2, but as R2 approaches 0.40, many methods tend to
perform similarly, though KNN(20)-MT nearly doubled the model size relative to other methods.
It is also notable that even EN, which performed very poorly in the settings displayed in row (a),
actually performs better than KNN(20)-MT in terms of prediction accuracy when the population
R2 = 0.40.
Finally, in the bottom row, (c), of Figure 2, results are displayed letting the proportion of
shared eQTLs vary with R2 = 0.10 fixed and ρ = 0.50 fixed. All methods which can exploit shared
eQTLs (i.e., all methods other than EN, tissue-by-tissue elastic net) improve in prediction accuracy
and LD-adjusted TPR as the proportion of shared eQTLs approaches one. Notably, our method
performs similarly in terms of prediction accuracy to Or-MT, which is not applicable in practice.
In addition, our method, Cov-MT, has higher LD-adjusted TPR than all other methods across all
proportions of shared eQTLs. This suggests that accounting for cross-tissue dependence may also
improve variable selection accuracy.
4 Genome-wide multi-tissue joint eQTL mapping in GTEx
In our analysis of the GTEx data, we focus on 29 types of human tissues (see Figure 1). These
are tissues which (i) are not sex-specific, (ii) had PEER factors and other covariates available from
GTEx, and (iii) are not brain or pituitary gland tissues. Brain and pituitary tissues were omitted
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Figure 3: (a, b): Left-out fold R2 averaged across five folds and all genes. In (a), dots correspond
to the average R2 for one tissue estimated by EN. In (b), dots correspond to the average R2 for one
tissue estimated using MT. In both (a) and (b), arrow heads point to the average R2 of the same
tissue using Cov-MT, and colors correspond to the sample sizes partitioned into intervals of size 100.
The points with no visible arrow in (b) had differences less than .0002 in absolute value. (c, d):
Differences in left-out fold R2 averaged across five folds and 29 tissues for each gene. In (c), we
display the difference using our method minus using EN. In (d), we display the difference using our
method minus using MT. In both, color gradients are used to improve visualization – darker colors
are farther from zero.
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because subjects which had expression measured in brain tissue often had no expression measured
in the other tissues and vice-versa.
We obtained RNA-seq data and whole genome-sequencing data from the GTEx Portal (gtexpor-
tal.org/home/, v7). We first filtered gene expression separately for each tissue based on read depth,
keeping only those genes whose 75th quantile read depth is at least 20. We then kept the intersec-
tion of all genes with sufficient read depth across all 29 tissues. Then, we transformed expression
using log2 {(ei,j,k + 1)/q0.75(ei,·,k)} where ei,j,k is the jth gene’s read depth for the kth tissue for the
ith subject, and q.75(ei,·,k) is the 75th quantile of that subject’s read depth within the kth tissue
across all genes. Finally, we adjusted for age, gender, three genotype principal components, and
PEER factors in the same way as described in Hu et al. [16] (i.e., using more PEER factors for
tissues with larger sample sizes). Specifically, we regressed the quantile-normalized expression onto
these covariates, and used the residuals as our normalized gene expression data for eQTL mapping.
For each gene, we considered only local eQTLs (cis-SNPs with MAF ≥ .05), which we defined
as SNPs within 500kb of the transcription start or end site of the gene. For each gene, we further
prune cis-SNPs until no two SNPs have absolute correlation greater than 0.95.
We performed joint eQTL mapping using the three approaches described in the Simulation
studies subsection. Following a similar approach to Hu et al. [16], we measured prediction accuracy
using a five-fold cross validation procedure. That is, each of the five folds was once treated as a
testing fold. Of the remaining four folds, three were used to train the model and one was used
as a validation set to select tuning parameters. Tuning parameters were selected to maximize the
average R2 on the validation set. We repeat this procedure for each of the five folds, with each fold
once serving as testing fold and once serving as validation fold.
Results are displayed in Figure 3, (a) and (b). In Figure 3(a), our method significantly improves
on the tissue-by-tissue elastic net in terms of prediction accuracy, especially for those tissue types
with small sample sizes. For example, in the tissue with the smallest sample size (Minor Salivary
Gland), the average testing-fold R2 for tissue-by-tissue elastic net was less than −0.05, indicating
that this approach performed significantly worse than the null model in terms of expression pre-
diction. This suggests that for small sample sizes, the tissue-by-tissue elastic net likely overfits to
the training data. Our method, on the other hand, had average testing fold R2 greater than 0.02
in all tissues, including Minor Salivary Gland. In Figure 3(b), we also compare Cov-MT to MT and
see that incorporating an estimate of the precision matrix Ω∗ improves testing fold R2 averaged
over genes and folds by 6.97% on the tissues we analyzed. Its important to point out that both
MT and Cov-MT select tuning parameters to maximize validation set R2 averaged over all tissues,
which may partly explain why Cov-MT improves the R2 on tissues with larger sample sizes – given
that these tissues have the highest frequency in the validation folds, they will play the largest role
in computing R2 averaged over all tissues.
In Figure 3(c) and Figure 3(d), we display differences in testing-fold R2 averaged across all
tissues and folds for each gene we analyzed. For example, each point in Figure 3(c) denotes the
difference in testing-fold R2 averaged over all tissues and folds for our method minus the average
using the tissue-by-tissue elastic net. Our method improved on tissue-by-tissue elastic net for nearly
every genes; whereas we improved over MT for a majority of genes. In particular, the summary
statistics for the difference displayed in Figure 3(d) (Cov-MT average minus MT average) are: Min
= −0.0161, Q1 = 3.806 × 10−5, Q2 = 0.001678, Mean = 0.001945, Q3 = 0.003685, and Max =
0.03959.
In Figure 4, we display a heatmap of how frequently our method estimated two tissues to
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Figure 4: A heatmap with frequencies of nonzero entries in the estimates of Ω∗. The diagonal has
been removed. Tissues were arranged to better visualize pairs which frequently nonzero conditional
correlations.
be conditionally dependent. As one would expect, biologically related tissues often had nonzero
estimated conditional correlations. For example, the three Esophagus tissues have some of the
largest numbers of genes with nonzero tissue-tissue conditional correlations. Similarly, Adipose-
Subcantaneous and Skin - Sun Exposed were often conditionally dependent, as were Skin - Not
Sun Exposed and Skin - Sun Exposed. Interestingly, many tissues rarely had nonzero estimated
conditional correlations with any other tissue: for example, see Small Intestine - Terminal Iluem,
Liver, Cells - EBV-transformed lymphocytes, and Minor Salivary Gland.
Another important point of scientific interest is the frequency with which two tissue types share
eQTLs. In Figure 5, we display a heatmap displaying the proportion of eQTLs shared between
pairs of tissues. The most notable result is that our method (and the method of Hu et al. [16]) tend
to estimate that the majority of eQTLs are shared across tissue types. For example, the first row of
Figure 5 indicates that of all estimated Adipose - Subcantaneous eQTLs, approximately 93% were
also estimated to be eQTLs for Adipose - Visceral and approximately 89% were also estimated to be
eQTLs for Adrenal Gland. Notably, Minor Salivary Gland and Cells-EBV-transformed lymphocytes
were the two tissues which had relatively low proportions of eQTLs shared with each of the other
tissues (indicated by the light vertical bands). This may be partly due to the small sample sizes
for both of these tissue types, which often led to fewer estimated eQTLs overall.
5 S-MultiXcan analysis of UKBiobank data
5.1 Multi-tissue transciptome-wide association studies
To demonstrate that our improved multi-tissue joint eQTL mapping method can lead to a higher
number of novel gene-level TWAS discoveries, we performed a summary-MultiXcan (S-MultiXcan)
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Figure 5: A heatmap of the proportions of eQTLs shared across tissue types. For a particular row,
the intensities correspond to the proportions of total eQTLs for that tissue which are also an eQTL
for the column-tissue. For example, the first row indicates that of all Adipose - Subcantaneous
eQTLs, approximately 93% are also eQTLs for Adipose - Visceral and approximately 89% are also
eQTLs for Adrenal Gland.
analysis following the method proposed in Barbeira et al. [2]. To obtain eQTL weights from the full
GTEx dataset, we re-estimated these coefficients using the complete dataset based on the tuning
parameters which had the largest average left-out fold R2. We then downloaded UKBiobank GWAS
summary statistics from the Neale [26] lab for four complex traits: two binary (asthma and heart
attack) and two continuous (haemoglobin and platelet count). These traits were selected as we
thought no single tissue-type was an obvious candidate for a single-tissue summary-PrediXcan
analysis. To compute the LD-matrices needed to perform the S-MultiXcan analysis, we used
whole genome-sequencing data obtained from the Genetics and Epidemiology of Colorectal Cancer
Consortium (GECCO), which was imputed using the Haplotype Reference Consortium (HRC)
reference panel. For each of the three eQTL weight set estimation methods, we tested only those
genes which had test set R2 averaged over all folds and tissues greater than zero. The number
of genes tested were 10289, 9321, 3701 for Cov-MT, MT, and EN respectively. When testing for
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association with each phenotype, we adjust for multiple tests using a Bonferonni correction. Thus,
EN, which has a smaller number of genes tested, also has a more liberal p-value cutoff.
For each gene, we recorded the S-MultiXcan p-value based on the weights computed using our
method, the exact version of the method proposed by Hu et al. [16], and tissue-by-tissue elastic
net (Cov-MT, MT, and EN, respectively). To validate our findings, we also recorded (a) the minimum
GWAS p-value amongst the SNPs which had nonzero weights across all methods for each gene, and
(b) the minimum GWAS p-value of any SNP with 500kb of the gene transcription start or end site.
This way, for any S-MultiXcan discovery, we verified whether this discovery could be attributed
to a genome-wide significant eQTL or SNP (based on (a) or (b), respectively) defined as p-value
< 5 × 10−8 or represents a potentially novel finding. In Table 1, we display the total number of
discoveries and the number of novel discoveries for two binary traits and two continuous traits.
The weight set obtained using MT, the exact version of the method propose by Hu et al. [16],
tended to include a larger number of SNPs. Conversely, our method, which yielded a slightly
smaller set of SNPS, has a similar or larger number of significant discoveries than MT. Further,
it also has more discoveries which could not be attributed to a GWAS associated eQTL or SNP
genotype. For instance, our method identified 18 significant genes, two-thirds did not have an eQTL
reaching genome-wide significance, and 3 with no cis-SNPs in the gene reaching the genome-wide
significance. In comparison, MT identified 13 genes, among which 7 and 1 gene(s) had no eQTLs or
cis-SNPs reaching genome-wide significance, respectively. These genes are listed in Table 2, along
with phenotypes with which these genes have been associated in previous GWAS studies (p-value
< 5 × 10−8) [3]. Notably, most of these genes are associated with phenotyopes related with heart
diseases such as coronary artery disease, blood level, cholesterol, high-density lipoproteins(HDL),
or low-density lipoproteins (LDL). When using the more stringent definition of a novel finding
based on the p-value of all cis-SNP genotypes, our method still identifies a higher number of novel
discoveries for both heart attack and platelet count. In the following section, we further discuss
the genes associated with heart attack which could not be attributed to a genome-wide significant
eQTL.
5.2 S-MultiXcan results
We have identified multiple genes associated with the occurrence of a heart attack that would be
missed in a SNP-by-SNP association analysis. Interestingly, many of these genes are associated with
phenotypes related to heart attack in previous GWAS, or are known to have biological functions
associated with the occurrence of a heart attack and coronary artery disease. A heart attack
occurs when an artery supplying the heart with blood and oxygen becomes blocked. This is closely
related to more broadly defined coronary artery disease, which is the narrowing or blockage of the
coronary arteries that leads to reduction of the amount of oxygen and nutrients delivered to the
heart. Coronary artery disease tends to develop when cholesterol or fatty deposits builds along the
artery walls.
Two genes that we identified in Table 2 are not associated with any phenotypes by previous
GWAS: BROX and ATG9B. The association with BROX may be due to its close proximity with
AIDA. ATG9B, on the other hand, functions in the regulation of autophagy and its expression
is induced by hypoxia in endothelial cells [7], and thus, is related to the reduction of oxygen
delivery which characterizes coronary artery disease. In fact, endothelial dysfunction is a hallmark
of coronary artery disease and another gene identified in our analysis, AIDA, was identified as a
coronary artery disease candidate gene by integrative analysis of vascular endothelial cell genomic
17
Table 1: Number of significant discoveries using different eQTL weights for two binary and two
continuous phenotypes. The bottommost two rows (with superscript ∗) denote the number of
discoveries which did not have an estimated eQTL reaching genome-wide significance (left) and did
not have any cis-SNP reaching genome-wide significance (right).
Asthma Heart Attack Haemoglobin Platelet
Cov-MT 10 18 890 1500
MT 11 13 866 1478
EN 6 11 368 600
Cov-MT∗ 6/3 12/3 185/68 245/55
MT∗ 3/3 7/1 183/68 228/47
EN∗ 2/1 4/1 71/36 89/37
Table 2: Genes associated with Heart Attack discovered in the S-MultiXcan analysis which could
not be attributed to a GWAS associated eQTL. In the rightmost two columns, we provide the
phenotypes which with the particular gene has been associated before according to the GWAS
Catalog as of October 21st, 2019 [3] for all the associations with p-value < 5×10−8. The phenotypes
for each gene are ranked by the number of times they are associated with this gene (indicated by
the numbers in the parenthesis next to the phenotype) and only top two phenotypes are shown
for each gene. Bold/underlined genes are those wherein no SNP within 500kb of TSS or TES was
genome-wide significant (including those not identified as eQTLs).
Gene Chr Region Associated phenotype 1 Associated phenotype 2
AIDA 1 222668013-222713210 Coronary artery disease (1)
BROX 1 222712553-222735196
FAM117B 2 202634969-202769757 Total cholesterol (2) LDL (2)
ICA1L 2 202773150-202871985 Heel bone mineral density (2) Total cholesterol (1)
CARF 2 202912214-202988263 Migraine (2) Coronary artery disease (1)
NBEAL1 2 203014879-203226378 Coronary artery disease (4) Adolescent idiopathic scoliosis (1)
ATG9B 7 151012209-151024499
LPL 8 19901717-19967259 Triglycerides (31) HDL (28)
FURIN 15 90868588-90883458 Systolic blood pressure (8) Schizophrenia (5)
FES 15 90883695-90895776 Systolic blood pressure (7) Diastolic blood pressure (4)
TGFB1 19 41301587-41353922 Blood protein levels (5) Coronary artery disease (5)
BCAM 19 44809059-44821421 Alzheimer’s disease (11) HDL (5)
features [17]. Several genes we have identified are involved in different biological processes related
with cancer development, implying some connections due to the hypoxia environment shared by
narrowed or blocked coronary artery and tumor micro-environment. For example, FES, TGFB and
BCAM are all well known cancer related genes involved in signaling for cell growth or apoptosis.
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CARF regulates cell proliferation and bridges cellular senescence and carcinogenesis [37]. A recent
report shows that FURIN inhibits apoptosis [47].
It is important to note that significant associations discovered in this paper do not imply
causality [38]. However, as the analysis is concerned with testing of predicted gene expression, it
has been shown that such associations are enriched in causal genes and these results should be
useful for investigating the disease mechanisms [1]. Further, when there is evidence for association
with predicted expression of a gene, we may further perform co-localization analysis using methods
proposed previously [48, 10, 15, 41] to examine whether any specific genetic variant is pleiotropic to
both the gene expression and disease risk, which may provide evidence of possible causal relationship
of the gene and disease.
6 Discussion
In this article, we have proposed a new method for obtaining multi-tissue eQTL weights. While our
method was motivated by the growing popularity of multi-tissue TWAS using genetically predicted
gene expression, it is notable that compared to tissue-by-tissue elastic net, our method yielded
eQTL weights which had higher prediction accuracy in every individual tissue we studied. This
suggests that even single-tissue PrediXcan analyses could be improved using our estimated weight
set. Of course, when to use a multi-tissue test versus a single-tissue test remains an unresolved and
important question. Our analyses focused on phenotypes for which no individual tissue seemed an
obvious candidate for analyses.
Another natural application of our method is for imputing unmeasured gene expression, e.g., as
was the goal of Wang et al. [40]. Specifically, Wang et al. [40] focused on the case of imputing missing
expression in GTEx in individuals with expression measured in a subset of tissues. Our method
naturally applies to this problem as the conditional expectation of the missing tissues’ expression
from (7) is easy to compute given estimates of eQTL weights and the cross-tissue error covariance
matrix. Furthermore, prediction (ellipsoids) intervals could be constructed using our estimates of
the conditional (co)variance of gene expression. Unlike Wang [39], who preselect eQTLs to be used
in their prediction model, our approach estimates eQTLs and fits the prediction model jointly.
Finally, it would be beneficial to extend our methodology to allow for more heavy-tailed error
distributions. For example, one could relax the normality assumption in (1) and assume that Y |
X = x follows a multivariate t-distribution. One interesting direction along these lines would modify
the method of Chen et al. [5] to handle missing data, which is highly nontrivial computationally.
Supplementary Material
In the Supplemental Material, we provide the complete algorithms used to solve both (9) and the ex-
act version of the estimator of Hu et al. [16], along with discussions of step size parameters. We also
include a user-guide for accessing our estimated eQTL weights in order to perform multi-tissue Mul-
tiXcan analyses using our weight set. Comprehensive results presented in the article, as well as soft-
ware to implement the method, are available for download at github.com/ajmolstad/MTeQTLResults.
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